Secondary hypereosinophilic syndrome

Get in touch with RARE Concierge.

Contact RARE Concierge

Synonyms: HES-R | Reactive hypereosinophilic syndrome | Secondary HES

A rare hypereosinophilic syndrome characterized by hypereosinophilia produced by reactive/non-clonal eosinophils secondary to an underlying medical condition and persisting for at least six months. The disorder can derive from non-neoplastic conditions (such as chronic infections and infestations allergic reactions intoxications or autoimmune and chronic inflammatory disorders) or from neoplasms including non-myeloid malignancies among others. It is associated with signs of organ infiltration dysfunction and damage. Clinical manifestations are highly variable depending on the organ systems involved and most commonly include dermatologic pulmonary cardiac gastrointestinal and cerebral manifestations.

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version May 2026

Newly diagnosed with
Secondary hypereosinophilic syndrome?

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Advocacy Organizations

American Partnership For Eosinophilic Disease

APFED is dedicated to preventing and curing eosinophil-associated diseases while enhancing the quality of life for patients and families. We achieve this by passionately embracing, supporting, and advancing education, awareness, research, advocacy, and support initiatives for those affected.

HeartCharged

Ending preventable deaths from undiagnosed heart conditions and sudden cardiac arrest, especially in young people, and providing patient-to-patient support.

website Location: Global

Don't see your organization here. Let us know here.

Clinical Trials

For a list of clinical trials in this disease area, please click here.